Biocell Laboratories, Inc.

Catalent is a global leader in providing integrated services, superior delivery technologies, and manufacturing solutions to help life science innovators develop and launch successful pharmaceuticals, biologics, and consumer health products. We have built an advanced range of technologies and capabilities and are dedicated to enabling a better and faster customer journey from product development to patient.

With over 85 years of experience, Catalent supports our partners in introducing 200 new products and manufacturing over 70 billion doses each year. We became a publicly traded company (NYSE: CTLT) in 2014 and have grown to become a vibrant community of approximately 15,500 + employees who support over 7,000 products for over 1,000 customers all around the world. At Catalent, we share a common goal: to put patients first and help people around the world live better and healthier lives.

Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. We have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging results.

more products. better treatments. reliably supplied.™

Your talents, ideas, and passion are essential to our mission: to develop, manufacture, and supply products that help people live better, healthier lives. Join us!

Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s advanced technologies and collaboration with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help bring life-enhancing products to life.

Grow with us. Be challenged. Make a personal impact.

Visit www.catalent.com/careers to explore career opportunities

Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.

Pharmaron is a contract research organization (CRO).

Services:
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services

www.pharmaron.com

CRO - Contract Research Organization
Library Synthesis
CADD
Bioorganic Chemistry
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
ChemInformatics
in vitro Biology
in vitro Screening
Structural Biology
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
Biomarkers
in vitro ADME
in vivo PK
PKPD
QA
Regulatory Affairs
Discovery Biologics
Process Chemistry
API Manufacturing
Material Science
Formulation Development
Drug Product Manufacturing
Toxicology
Safety Pharmacology
Genetic Toxicology
DART
Pathology
Immunotoxicity
Bioanalytical
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
QWBA
mARG
Clinical AME
Mass Balance
Metabolite Profiling
Microdosing Phase 0
Absolute Bioavailability
DDI
First-in-Human (FIH)
Thorough QT(TQT)
Ethnobridging

Access Biologicals LLC is an industry leader in the collection and manufacturing of an extensive portfolio of biological products. Combined with closed-loop material sourcing, we are able to provide critical support for various markets such as in-vitro diagnostic manufacturing, biopharmaceutical, cell culture and diagnostic research & development. Viral testing and donor examinations are performed in accordance with current State, CLIA and FDA regulations allowing us to deliver consistently high quality human blood products. Manufacturing capabilities include a variety of plasma and serum processing in fully auditable facilities with on-site monitored storage. Our high throughput laboratory provides customer-driven responsiveness to specifications and product requirements. Our cell culture division offers a variety of human and animal sera products, and is the only company to directly collect and process Human AB serum at FDA licensed facilities located within the US.



Our headquarters, manufacturing facility and comprehensive donor recruitment office is located in Vista, CA. Sales offices are located in Dartmouth, MA, Atlanta, GA and Philadelphia, PA. Saturn Biomedical, our state-of-the-art plasma and blood collection center in Indianapolis, IN, is uniquely positioned as the largest and newest specialty donor center in the United States.

FDA/CLIA/ISO licenses

FDA Registration # 307234900 – Access Manufacturing
FDA Registration # 3006118943 – Access Biologicals
CLIA Certification ID # 15D0891286 – Access Plasma dba Saturn Bio
FDA License # 1193 – Access Plasma dba Saturn Bio
ISO 9001 Certified

Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and hemostasis research and diagnostics. Our products include an extensive line of antibodies, conjugates, antibody pairs for immunoassay of human and animal analytes, the VisuLize line of complete ELISA kits, and a full line of human plasma products including VisuDep Immune-Depleted Factor-Deficient Plasmas, VisuCal Calibrator Plasma and VisuCon Control Plasmas. Services include protein purification, antibody production, assay development, custom manufacturing including custom lyophilization and proficiency testing materials.

For more information please visit www.affinitybiologicals.com.

Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc., Akston’s COVID-19 vaccine candidate is in Phase II trials in the Netherlands. It has partnered with Dechra Pharmaceuticals PLC to commercialize once-a-week canine and feline insulin therapies. The company employs 35 people, has over 3,500 ft2 of research laboratory space and a 12,400 ft2 GMP clean room biologics manufacturing facility.